← Back to headlines
Eli Lilly Signs $1.9 Billion Gene-Editing Deal with Ascidian Therapeutics
Eli Lilly has entered into a gene-editing agreement with Ascidian Therapeutics, potentially worth up to $1.9 billion. This deal focuses on RNA editing technology.
3 Jun, 13:09 — 3 Jun, 14:02
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
Yahoo
Center
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
Coverage Timeline
First report: seeking-alpha · 3 Jun, 13:09|Full coverage: 2 · 54m|Window: 54m
Left-leaningCenterRight-leaning
